(1) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes, Zinman et al., fort he EMPA-REG OUTCOME Investigators; N Engl J Med 2015; 373:2117-2128
DOI: 10.1056/NEJMoa1504720
(2) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure, Packer et al., for the EMPEROR-Reduced Trial Investigators; N Engl J Med 2020; 383:1413-1424